Corneal Cross-Linking: A Breakthrough in Treating Keratoconus.

Amina Bello*

Department of Pediatric Ophthalmology, University of Lagos, Nigeria

Introduction

Keratoconus is a progressive eye disease characterized by thinning and bulging of the cornea, which leads to visual distortions and impaired vision. Traditional treatments for keratoconus, such as glasses or contact lenses, are often inadequate as the disease progresses. However, recent advances in ophthalmology have introduced corneal cross-linking (CXL) as a groundbreaking treatment option. This article explores the mechanism, benefits, and implications of corneal cross-linking in treating keratoconus [1].

Keratoconus is a condition where the normally round cornea becomes thin and protrudes into a cone-like shape. This deformation disrupts the cornea's ability to focus light properly, resulting in blurred or distorted vision. The disease typically begins in the teenage years or early adulthood and can progress over time, significantly affecting a patient's quality of life. Corneal cross-linking (CXL) is a minimally invasive procedure designed to halt the progression of keratoconus by strengthening the corneal tissue. The technique involves increasing the rigidity of the cornea, which helps to stabilize its shape and prevent further deformation [2,3].

The procedure starts with the removal of the epithelium, the outermost layer of the cornea. This step ensures that the underlying stroma, where cross-linking will occur, is exposed. A riboflavin solution (vitamin B2) is then applied to the cornea. Riboflavin acts as a photosensitizer that absorbs ultraviolet (UV) light. The cornea is exposed to ultraviolet A (UVA) light for a specified period. The interaction between the UVA light and riboflavin triggers the formation of cross-links between collagen fibers in the corneal stroma [4].

The new cross-links enhance the mechanical strength and stability of the cornea. This stabilization helps to prevent further progression of keratoconus and can improve visual acuity in many cases. One of the primary benefits of CXL is its ability to stop the progression of keratoconus. By strengthening the cornea, CXL prevents further thinning and bulging, preserving vision and reducing the need for more invasive procedures. Although CXL is not a cure for keratoconus, it can lead to improvements in visual acuity. Some patients experience a reduction in the need for corrective lenses or achieve better vision with their existing lenses [5,6].

The procedure is relatively simple and involves only a small incision or none at all. Most patients can return to their daily activities within a few days, and the risk of serious complications is low. Studies have shown that CXL provides long-lasting benefits, with many patients maintaining improved corneal stability for years after the procedure. Patients may experience discomfort, light sensitivity, and blurred vision in the days following the procedure. This is generally temporary and improves as the cornea heals [7].

As with any surgical procedure, there is a risk of infection. Proper post-operative care and adherence to prescribed treatments can help minimize this risk. In rare cases, scarring of the cornea can occur, which may affect vision. Monitoring and follow-up care are essential to address any issues that arise. While CXL can halt the progression of keratoconus and improve visual acuity, it does not reverse existing damage. Patients may still require corrective lenses or other treatments [8].

Regular follow-up visits with an ophthalmologist are crucial to monitor the healing process and ensure that the cornea is stabilizing as expected. Patients are typically prescribed antibiotic and anti-inflammatory eye drops to prevent infection and manage inflammation. Patients should avoid rubbing their eyes, which can disrupt the healing process and increase the risk of complications. Wearing sunglasses and avoiding exposure to bright lights can help alleviate discomfort and protect the healing cornea [9].

Recent advancements in corneal cross-linking technology are enhancing the effectiveness and safety of the procedure. Innovations include: This technique involves performing CXL without removing the epithelium, reducing discomfort and speeding up recovery. Advances in imaging technology allow for more precise treatment planning based on individual corneal topography, improving outcomes. New riboflavin solutions with improved absorption and penetration properties are being developed to optimize the cross-linking process [10].

Conclusion

Corneal cross-linking represents a significant advancement in the management of keratoconus, offering a promising option for halting disease progression and improving visual acuity. By understanding the procedure, its benefits, and potential risks, patients and healthcare providers can make informed decisions about treatment. Ongoing research and technological advancements continue to refine and enhance the effectiveness of CXL, providing hope for better outcomes and quality of life for individuals with keratoconus.

***Correspondence to:** Amina Bello, Department of Pediatric Ophthalmology, University of Lagos, Nigeria, E-mail: abello@unilag.edu.ng

***Received:** 03-Aug-2024, Manuscript No. OER-24-144386; **Editor assigned:** 05-Aug-2024, Pre QC No. OER-24-144386 (PQ); **Reviewed:** 19-Aug-2024, QC No. OER-24-144386; **Revised:** 25-Aug-2024, Manuscript No. OER-24-144386(R); **Published:** 30-Aug-2024, DOI: 10.35841/oer-8.4.227*

***Citation:** Bello A. Corneal Cross-Linking: A Breakthrough in Treating Keratoconus. Ophthalmol Case Rep. 2024; 8(4):227*

References

1. Wollensak G, Spoerl E, Seiler T. Riboflavin/ ultraviolet-A–induced collagen crosslinking for the treatment of keratoconus. Am J Ophthalmol. 2003;135(5):620-7.
2. Ghiasian L, Abolfathzadeh N, Manafi N. Intraocular lens power calculation in keratoconus; A review of literature. J Curr Ophthalmol. 2019;31(2):127-34.
3. Hassan Z. Our results with modern diagnostic and therapeutic methods in ectatic corneal diseases and in refractive surgery.
4. Hamada S, Barua A, Caporossi A, et al. Corneal cross-linking in children. Corneal. 2017:229-68.
5. Masterton S, Ahearne M. Mechanobiology of the corneal epithelium. Exp Eye Res. 2018;177:122-9.
6. Ziaei M. Novel Options for the Treatment of Corneal Disease.
7. Kymionis GD, Kontadakis GA, Kounis GA, et al. Simultaneous topography-guided PRK followed by corneal collagen cross-linking for keratoconus. J Refract Surg. 2009;25(S3):S807-11.
8. Hosur V, Thanthri V. Acute Pulmonary Edema in a Patient undergoing Appendectomy under Spinal Anesthesia. J Med Sci. 2017;3(3):76-8.
9. Zotta PG, Diakonis VF, Kymionis GD. Long-term outcomes of corneal cross-linking for keratoconus in pediatric patients. J Pediatr Ophthalmol Strabismus. 2017;21(5):397-401.
10. Shajari M, Kolb CM, Agha B, et al. Comparison of standard and accelerated corneal cross-linking for the treatment of keratoconus: a meta-analysis. Acta Ophthalmol. 2019;97(1):e22-35.

Citation: *Bello A. Corneal Cross-Linking: A Breakthrough in Treating Keratoconus. Ophthalmol Case Rep. 2024; 8(4):227*